Tip of the 'Spero': Roche, start-up target new antimicrobial pathway

By Marie PowersStaff Writer

Wednesday, April 9, 2014

Just a year out of the gate, Atlas Venture-backed Spero Therapeutics LLC snagged Roche AG as a partner to develop anti-infectives for drug-resistant bacterial infections, targeting a pathway that involves both virulence and persistence of gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa).